GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sichuan Kelun Pharmaceutical Co Ltd (SZSE:002422) » Definitions » EBIT

Sichuan Kelun Pharmaceutical Co (SZSE:002422) EBIT : ¥4,374 Mil (TTM As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Sichuan Kelun Pharmaceutical Co EBIT?

Sichuan Kelun Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥1,672 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥4,374 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sichuan Kelun Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2024 was 19.76%. Sichuan Kelun Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 40.12%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sichuan Kelun Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 8.79%.


Sichuan Kelun Pharmaceutical Co EBIT Historical Data

The historical data trend for Sichuan Kelun Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun Pharmaceutical Co EBIT Chart

Sichuan Kelun Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,841.12 1,509.89 1,695.95 2,541.63 3,941.96

Sichuan Kelun Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,240.74 842.31 753.95 1,104.97 1,672.43

Competitive Comparison of Sichuan Kelun Pharmaceutical Co's EBIT

For the Drug Manufacturers - General subindustry, Sichuan Kelun Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Kelun Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sichuan Kelun Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun Pharmaceutical Co's EV-to-EBIT falls into.



Sichuan Kelun Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4,374 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sichuan Kelun Pharmaceutical Co  (SZSE:002422) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sichuan Kelun Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=6320.9 * ( 1 - 20.86% )/( (25079.807 + 25543.474)/ 2 )
=5002.36026/25311.6405
=19.76 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=36454.901 - 5008.532 - ( 6366.562 - max(0, 9993.11 - 18290.027+6366.562))
=25079.807

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=37676.458 - 5302.093 - ( 6830.891 - max(0, 9692.237 - 19208.487+6830.891))
=25543.474

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sichuan Kelun Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=6689.724/( ( (12085.501 + max(4576.123, 0)) + (12268.276 + max(4417.233, 0)) )/ 2 )
=6689.724/( ( 16661.624 + 16685.509 )/ 2 )
=6689.724/16673.5665
=40.12 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4682.762 + 3839.798 + 1801.015) - (5008.532 + 0 + 738.92)
=4576.123

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4969.552 + 3536.918 + 1808.08) - (5302.093 + 0 + 595.224)
=4417.233

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sichuan Kelun Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=4373.657/49784.434
=8.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sichuan Kelun Pharmaceutical Co EBIT Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun Pharmaceutical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Kelun Pharmaceutical Co (SZSE:002422) Business Description

Traded in Other Exchanges
N/A
Address
No.36 West Baihua Road, Qingyang District, Chengdu, CHN, 610071
Sichuan Kelun Pharmaceutical Co Ltd is a China-based Pharmaceutical company mainly focused on the production and sales of injection products, including products for glucose injection and sodium chloride injection. It manufactures and sells high-volume injections (infusions), small-volume injections (water needles), sterile powder injections (containing powdered and freeze-dried powder). Its products include tablets, capsules, capsules, granules, oral liquids, peritoneal dialysis fluids, raw material medicines, medical packaging materials, medical instruments, and antibiotic intermediates.
Executives
Lai De Gui Executives
Feng Hao Directors, executives
Liu Si Chuan Directors, executives
Wang Jing Yi Directors, executives
Wan Yang Yu Executives
Ge Jun You Executives
Wu Zhong Hua Executives
Wan Peng Supervisors
Tan Hong Bo Executives
Liu Ge Xin Director
Huang Xin Securities Affairs Representative
Ge Tao Executives
Pan Hui Directors, executives
Zhou Xiao Dong Executives
Zheng Chang Yan Supervisors

Sichuan Kelun Pharmaceutical Co (SZSE:002422) Headlines

No Headlines